Pall — FY2012 Earnings Presentation
32 slides from Pall's earnings presentation, Sep 13, 2012
Slide 1: Q4 and Full Year FY 2012 Financial Results
Better Lives. Better Planet.SM Q4 and Full Year FY 2012 Financial Results September 13, 2012 Exhibit 99.2
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for fiscal year 2012 are preliminary until the Company's Form 10-K is filed with the Securities and Exchange Commission on or before October 1
Slide 3: Conference Call Replay Info
3 Conference Call Replay Info • Toll-Free: 855.859.2056 • International: 404.537.3406 • Conference ID: 26044759 • Internet: www.pall.com/investor
Slide 4: Agenda
4 Agenda • Pall Outlook and FY 2012 Summary • Q4 and FY 2012 Performance • FY 2013 Guidance • Q&A All remarks in this presentation are on a “Continuing Operations” basis, which excludes the results of the Blood product line divestiture, unless indicated otherwise.
Slide 5: FY 2012 Summary & Outlook
5 FY 2012 Summary & Outlook • Record quarter despite headwinds • Progress on People, Process and Technology initiatives • Capital allocation priorities • Structural cost improvement initiative • Macro environment and headwinds Value Creation in a Volatile Economy
Slide 6: Financial Overview
6 $2,517 $2,672 $719 $722 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 Revenue % Growth Excluding FX Q4 Full Year Financial Overview (a) See Reconciliation of Non-GAAP Financial Measures to their GAAP Counterparts in Appendix (b) Free Cash Flow from total operations Dollars in Millions, except EPS dat
Slide 7: Sales by Segment
7 Fourth Quarter Life Sciences Consumables $306 +13.7% Industrial Consumables $301 +4.6% Industrial Systems $87 +7.3% Life Sciences Systems $28 (-30.5%) 42% 42% 12% 4% Sales by Segment Life Sciences Consumables $1,133 +7.0% Industrial Consumables $1,159 +5.5% Full Year Industrial Systems $259 +14.8%
Slide 8: Life Sciences Q4 Sales & Orders
8 Life Sciences Q4 Sales & Orders Sales Consumables • BioPharmaceuticals +19.8% − Strength in the biotech sector − ForteBio acquisition added $7mm (~4%) • Food and Beverage +4.5% − Organic growth ~+12% − New applications and products − Low margin systems rationalization • Medical +1.9% − Driven by I
Slide 9: Life Sciences Full Year Sales & Orders
9 Life Sciences Full Year Sales & Orders Sales Consumables • BioPharmaceuticals +12.1% – ForteBio acquisition added $13mm (~2%) • Food and Beverage (-2.5%) − Organic growth ~+4% • Medical (-1.3%) − Reduced hospital spending due to governmental/budget pressure Systems • Double-digit growth in BioPhar
Slide 10: Industrial Q4 Sales & Orders
10 Industrial Q4 Sales & Orders Sales Consumables • Process Technologies (-0.2%) − Lower volume of capital goods shipments in Energy Market − Increased sales to Machinery & Equipment OEMs • Aerospace +21.6% − Military +31% and Commercial +11% − Strong demand for spares • Microelectronics +2.2% − Inc
Slide 11: Industrial Full Year Sales & Orders
11 Industrial Full Year Sales & Orders Sales Consumables • Process Technologies +8.0% − Growth in all underlying markets • Aerospace +12.2% − Military +20.5% and Commercial +3.8% • Microelectronics (-3.5%) − Semiconductor production in Asia remained weak − Displays weak; data storage negatively impa
Slide 12: Q4 Sales & Orders by Region
12 Q4 Sales & Orders by Region Dollars in millions Sales and orders changes exclude FX Americas Sales • Past due customer order reduction • Acquisitions +~4% • Organic growth +~7% • Latin America +~25%−aided by Brazilian distributor acquisition Orders • Recovery demand from Q3 • Strong growth in Lat
Slide 13: Segment Performance: Gross and Segment Margin
13 0% 10% 20% 30% 40% 50% Q4 Year Q4 Year 46.0% +280 bps 43.2% 45.9% +10 bps 45.8% 17.4% +490 bps 12.5% 14.0% +30 bps 13.7% Gross Margin Segment Margin Segment Performance Life Sciences Q4 • BioPharm consumables favorable mix, pricing and sales channel change drove Q4 gross margin improvement; FX he
Slide 14: Financial Overview and Pro forma EPS Bridge
14 $2,517 $2,672 $719 $722 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 Revenue % Growth Excluding FX Q4 Full Year Financial Overview (a) See Reconciliation of Non-GAAP Financial Measures to their GAAP Counterparts in Appendix Dollars in Millions, except EPS data $2.42 $2.80 $0.65 $0.86 $- $0.50 $1.00
Slide 15: Cash Flow and Working Capital
15 Cash Flow and Working Capital Full Year FY12 Full Year FY11 Operating Cash Flow 475$ 430$ CapEx (159) (161) Free Cash Flow 316$ 269$ Other Significant Uses of Cash: Acquisition of businesses (168)$ -$ Dividends (89) (78) Repayment under Financing Facilities (10) (89) Stock Buybacks (121) (150) Da
Slide 16: Impact of the Blood Divestiture
16 Impact of the Blood Divestiture • Completed the divestiture of the business assets of the blood collection, filtration and processing product lines on August 1, 2012 • Received ~$440mm(1) of cash proceeds, after pro forma tax, upon closing • FY 2012 Blood Financial Results: – Revenue ~$230mm – Op
Slide 17: FX Risk
17 FX Risk BOY = Beginning of year, Gross profit numbers in Dollars in millions (a) As at July 31, 2012 U S D a n d GBP E q u iv a le n t o f E u ro ( a ) 14% 11% FY2012 Weighted Average 2013 Assumptions Δ % GBP/Euro 0.84 0.79 (-6%) USD/Euro 1.32 1.25 (-5%) Currency Pair Analysis • We continue to ha
Slide 18: Challenging Macro Environment
18 Challenging Macro Environment Global macroeconomic concerns are exacerbated by negative real growth rates Nominal GDP Growth CPI Inflation Real GDP Growth(1) 2010 2011 2012E 2013E Source: BofA Merrill Lynch Global Economic Weekly report dated September 7, 2012. (1) Real GDP growth calculated as N
Slide 19: FY 2013 Outlook
19 Revenue • Low to mid single digit growth Pro Forma EPS • $3.05 – $3.25 • Represents growth of 9% – 16% • Estimate excludes Discrete Items, future acquisitions and related costs FY 2013 Outlook Other Key Assumptions • Gross Margins − 20-40 bps improvement − Includes ~$10mm of structural cost impro
Slide 20: FY 2013 Outlook: 2012 to 2013E EPS Walk
20 FY 2013 Outlook (cont’d) 2012 to 2013E EPS Walk Low High FY 2012 EPS 2.80$ 2.80$ Sales Growth 0.20 0.41 Structural Cost Improvement 0.30 0.30 FX (0.22) (0.24) Tax Rate (0.03) (0.03) Share Repurchase 0.10 0.11 R&D Investment (0.10) (0.10) FY 2013E EPS 3.05$ 3.25$
Slide 21: Appendix
Better Lives. Better Planet.SM Appendix
Slide 22: Appendix: Earnings from Continuing and Discontinued Operations
22 Appendix: Earnings from Continuing Operations Reconciliation of Non-GAAP Financial Measures Discontinued Operations Fourth Quarter Diluted EPS as reported 0.64$ 0.76$ 0.09$ Tax Adjustments (0.01) (0.16) - Interest Adjustments (0.02) (0.03) - Restructuring and Other Charges (ROTC), after pro forma
Slide 23: Appendix: Q4 Life Sciences Sales By Market & Technology
23 Appendix: Q4 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Consumables Sales: BioPharmaceuticals 204.8$ (13.5)$ 218.3$ 182.3$ 19.8% Medical 51.5 (3.6) 55.1
Slide 24: Appendix: Full Year Life Sciences Sales By Market & Technology
24 Appendix: Full Year Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY12 Full Year FY12 Estimated Impact of FX Full Year FY12 Estimate Excluding FX Full Year FY11 % Change Excluding FX Consumables Sales: BioPharmaceuticals 754.9$ (8.3)$ 763.2 681
Slide 25: Appendix: Q4 Industrial Sales By Market & Technology
25 Appendix: Q4 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Consumables Sales: Process Technologies 151.5$ (9.8)$ 161.3$ 161.5$ (0.2%) Aerospace 66.6 (2.0) 68.
Slide 26: Appendix: Full Year Industrial Sales By Market & Technology
26 Appendix: Full Year Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY12 Full Year FY12 Estimated Impact of FX Full Year FY12 Estimate Excluding FX Full Year FY11 % Change Excluding FX Consumables Sales: Process Technologies 627.6$ (6.4)$ 634.0$ 587
Slide 27: Appendix: Q4 Sales by Segment and Region
27 Appendix: Q4 Sales by Segment and Region Reconciliation of Non-GAAP Financial Measures Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Life Sciences Sales: Americas 114.4$ (1.5)$ 115.9$ 94.8$ 22.2% Europe 146.1 (19.5) 165.6 168.9 (2.0%) Asia 74.2
Slide 28: Appendix: Q4 Orders by Technology
28 Appendix: Q4 Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in millions Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Life Sciences Orders: Consumables 299.6$ (22.1)$ 321.7$ 281.2$ 14.4% Systems 39.8 (2.9) 42.7 37.4
Slide 29: Appendix: Full Year Orders by Technology
29 Appendix: Full Year Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in millions Full Year FY12 Full Year FY12 Estimated Impact of FX Full Year FY12 Estimate Excluding FX Full Year FY11 % Change Excluding FX Life Sciences Orders: Consumables 1,156.3$ (12.5)$ 1,168.8$ 1,0
Slide 30: Appendix: Q4 Operating Profit
30 Appendix: Q4 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q4 FY12 Q4 FY11 Life Sciences segment profit 86.1$ 78.8$ Industrial segment profit 67.6 48.5 Total segment profit 153.7$ 127.3$ General corporate expenses (14.3) (15.4) Ope ating profit 139.4$ 111.9$ % of
Slide 31: Appendix: Full Year Operating Profit
31 Appendix: Full Year Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Full Year FY12 Full Year FY11 Life Sciences segment profit 319.3$ 292.5$ Industrial segment profit 198.8 182.7 Total segment profit 518.1$ 475.2$ General corporate expenses (64.1) (61.1) Operating
Slide 32: Better Lives. Better Planet.
Better Lives. Better Planet.SM www.pall.com/green